Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial

https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00289-5/abstract?utm_campaign=update-laninf&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_laninf&_hsenc=p2ANqtz--xsqEfi-BXBy5cQuZY7SeACW7mM4WJ2QB2iT5m9nbl9ZXKz7p2mFWGGqev8eOTcH7mgWOJWLWXcHzeZxrInkdxDnwHpQ&_hsmi=328184754&utm_content=328157856&utm_source=hs_email